Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
BAVARIAN NORDIC R/I S/ADR (BVNRY)
NASDAQ:AMEX Investor Relations:
bavarian-nordic.com/investor.aspx
Company Research
Source: GlobeNewswire
COPENHAGEN, Denmark, January 25, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma has completed recruitment of the planned 10 patients ahead of schedule. The multi-site trial, which holds the potential to serve as a registration trial, aims to determine if the combination of BN-Brachyury vaccine and the current standard of care, radiation therapy, results in a clinically meaningful objective response rate (ORR) within 12 months of radiation therapy, a timeframe during which historical controls show an ORR of less than 5% with radiation alone. Radiation has been shown to inflame the tumor, releasing cancer antigens. BN-Brachyury is designed to teach T cells to attack brachyury-expressing cells and kill the tumor cells. As per the study design, the first 10 patients have now been enrolled, thus completing recruitme
Show less
Read more
Impact Snapshot
Event Time:
BVNRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVNRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVNRY alerts
High impacting BAVARIAN NORDIC R/I S/ADR news events
Weekly update
A roundup of the hottest topics
BVNRY
News
- Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS®, the Only FDA-approved Mpox Vaccine [Yahoo! Finance]Yahoo! Finance
- Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S. [Yahoo! Finance]Yahoo! Finance
- Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.GlobeNewswire
- Mpox cases in the US are on the rise as vaccination rates lag and new threats loom [CNN]CNN
- Mpox cases in the US are on the rise as vaccination rates lag and new threats loom [CNN]CNN